美国 · SEC FORM 4
Cadre Holdings, Inc.
CDRE · NYSE · CIK 0001860543 · Healthcare · Aerospace & Defense
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
13 同一窗口内观察到的 Form 4 交易行
11 sales · 2 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2021-11-08 · Browers Blaine.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 1,979,273
- 上期报告
- 2,257,405
- 日均成交量
- 605,757
- 回补天数
- 3.3
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
Form 4 申报证据
42 transaction lines in the latest 365-day window; 213 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | KANDERS WARREN B | 卖出 (S) | Common Stock | 100,000 | USD 31.87 | USD 3,187,045 | SEC 申报 ↗ |
| 2026-08-24 | KANDERS WARREN B | 卖出 (S) | Common Stock, par value $0.0001 per share ("Common Stock") | 65,431 | USD 33.20 | USD 2,172,309 | SEC 申报 ↗ |
| 2026-08-24 | KANDERS WARREN B | 卖出 (S) | Common Stock | 34,569 | USD 33.65 | USD 1,163,247 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | KANDERS WARREN B | 卖出 (S) | Common Stock | 100,000 | USD 31.87 | USD 3,187,045 | SEC 申报 ↗ |
| 2026-08-24 | KANDERS WARREN B | 卖出 (S) | Common Stock, par value $0.0001 per share ("Common Stock") | 65,431 | USD 33.20 | USD 2,172,309 | SEC 申报 ↗ |
| 2026-08-24 | KANDERS WARREN B | 卖出 (S) | Common Stock | 34,569 | USD 33.65 | USD 1,163,247 | SEC 申报 ↗ |
| 2026-08-17 | Williams Brad | 卖出 (S) | Common Stock | 88,742 | USD 33.24 | USD 2,949,898 | SEC 申报 ↗ |
| 2026-08-17 | Williams Brad | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 42,770 | USD 23.45 | USD 1,002,956 | SEC 申报 ↗ |
| 2026-08-17 | Williams Brad | 期权行权/转换 (M) | Common Stock | 45,972 | USD 20.53 | USD 943,805 | SEC 申报 ↗ |
| 2026-06-22 | KANDERS WARREN B | 卖出 (S) | Common Stock | 50,000 | USD 27.43 | USD 1,371,500 | SEC 申报 ↗ |
| 2026-06-18 | KANDERS WARREN B | 卖出 (S) | Common Stock, par value $0.0001 per share ("Common Stock") | 25,000 | USD 27.86 | USD 696,500 | SEC 申报 ↗ |
| 2026-06-17 | KANDERS WARREN B | 卖出 (S) | Common Stock | 25,000 | USD 28.68 | USD 717,000 | SEC 申报 ↗ |
| 2026-06-16 | KANDERS WARREN B | 卖出 (S) | Common Stock | 100,000 | USD 28.19 | USD 2,819,000 | SEC 申报 ↗ |
| 2026-06-15 | KANDERS WARREN B | 卖出 (S) | Common Stock, par value $0.0001 per share ("Common Stock") | 100,000 | USD 30.03 | USD 3,003,000 | SEC 申报 ↗ |
| 2026-03-23 | KANDERS WARREN B | 卖出 (S) | Common Stock | 100,000 | USD 31.93 | USD 3,193,000 | SEC 申报 ↗ |
| 2026-03-20 | KANDERS WARREN B | 卖出 (S) | Common Stock, par value $0.0001 per share ("Common Stock") | 100,000 | USD 31.40 | USD 3,140,000 | SEC 申报 ↗ |
| 2026-03-18 | Williams Brad | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 4,508 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-18 | Williams Brad | 代扣税 (F) | Common Stock | 1,098 | USD 32.22 | USD 35,378 | SEC 申报 ↗ |
| 2026-03-18 | KANDERS WARREN B | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 11,180 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-18 | KANDERS WARREN B | 代扣税 (F) | Common Stock | 4,400 | USD 32.22 | USD 141,768 | SEC 申报 ↗ |
| 2026-03-18 | Browers Blaine | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 3,282 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-18 | Browers Blaine | 代扣税 (F) | Common Stock | 1,292 | USD 32.22 | USD 41,628 | SEC 申报 ↗ |
| 2026-03-13 | Williams Brad | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 4,191 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | Williams Brad | 期权行权/转换 (M) | Common Stock | 5,170 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | Williams Brad | 代扣税 (F) | Common Stock | 2,409 | USD 31.65 | USD 76,245 | SEC 申报 ↗ |
| 2026-03-13 | KANDERS WARREN B | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 11,455 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | KANDERS WARREN B | 期权行权/转换 (M) | Common Stock | 12,556 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | KANDERS WARREN B | 代扣税 (F) | Common Stock | 9,449 | USD 31.65 | USD 299,061 | SEC 申报 ↗ |
| 2026-03-13 | Browers Blaine | 期权行权/转换 (M) | Common Stock, par value $0.0001 per share ("Common Stock") | 3,393 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | Browers Blaine | 期权行权/转换 (M) | Common Stock | 4,309 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | Browers Blaine | 代扣税 (F) | Common Stock | 3,181 | USD 31.65 | USD 100,679 | SEC 申报 ↗ |
| 2025-12-24 | KANDERS WARREN B | 赠与 (G) | Common Stock, par value $0.0001 per share ("Common Stock") | 12,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-12 | Browers Blaine | 卖出 (S) | Common Stock, par value $0.0001 per share ("Common Stock") | 20,435 | USD 43.79 | USD 894,849 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CDRE |
| CIK | 0001860543 |
| 行业 | Healthcare |
| 细分行业 | Aerospace & Defense Yahoo Finance |
| SEC SIC | 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 213 transaction lines from 2021-11-08 to 2026-08-25 2 P purchase lines · 121 S sale lines · 90 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.